Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Nuclera expands eProtein Discovery capabilities to enable membrane protein production

Nuclera, the biotechnology company accelerating protein expression and optimization through its benchtop eProtein Discovery™ system, today announced the addition of a new membrane protein workflow to its system.

From Nuclera 16 Apr 2025

Researchers analyze the mutational landscape of TMB-high colorectal cancer tumors

Colorectal cancer (CRC), a type of cancer that affects the large intestine and rectum, is one of the leading causes of cancer-related deaths worldwide.

15 Apr 2025

New antibiotic compound emerges as strong candidate in the fight against MRSA

The development of new antibiotics to treat superbugs and other bacterial infections is a global priority, with the rate of infections that cannot be treated with current antibiotics rising and presenting one of the biggest threats to human health.

10 Apr 2025

Calibr-Skaggs receives FDA approval to test sCAR-T therapy in patients with autoimmune diseases

Calibr-Skaggs Institute for Innovative Medicines, the drug discovery division of Scripps Research, announced today that the FDA has cleared their investigational new drug (IND) application to study switchable chimeric antigen receptor T cell (sCAR-T) therapy (CLBR001 + SWI019) in patients with autoimmune conditions.

9 Apr 2025

Advancing Adherent Cell Assays with SemaCyte® Technology

Semarion's SemaCyte® technology transforms adherent cell assays, enabling faster, automated workflows that enhance scalability and efficiency in drug discovery.

From Semarion 9 Apr 2025

National Quantum Computing Centre launches Insights Paper exploring quantum computing's transformative potential in healthcare and pharmaceuticals

Today, the National Quantum Computing Centre (NQCC) launched its first Insights Paper, "The convergence of healthcare and pharmaceuticals with quantum computing: A new fronter in medicine", exploring how quantum computing could enable a step-change in medicine and healthcare delivery over the coming decades.

From NQCC 4 Apr 2025

OICR funds five innovative cancer drug discovery projects

The Ontario Institute for Cancer Research (OICR) has announced its support for five Ontario research teams working to develop the next generation of medicines that kill tumours more effectively, cause fewer side effects and reduce the risk that cancer will come back.

3 Apr 2025

New structural and mechanistic understanding for cancer drug design

A University of Iowa-led study has revealed the unexpected structure adopted by the DNA repair protein RAD52 as it binds and protects replicating DNA in dividing cells. This new structural and mechanistic understanding of the RAD52-DNA complex may help researchers develop new anti-cancer drugs.

3 Apr 2025

Mount Sinai launches AI center to revolutionize small molecule drug discovery

The Icahn School of Medicine at Mount Sinai has launched the AI Small Molecule Drug Discovery Center, a bold endeavor that harnesses artificial intelligence (AI) to revolutionize drug development.

2 Apr 2025

WHO releases first reports on shortages in fungal disease treatments and diagnostics

The World Health Organization (WHO) today published its first-ever reports addressing the critical lack of medicines and diagnostic tools for invasive fungal diseases, showing the urgent need for innovative research and development (R&D) to close these gaps.

2 Apr 2025

Assessing the impact of the particle drift effect on oral drug absorption using flux tools

Discover how particle drift analysis using flux tools improves oral drug absorption in pharmaceutical research.

From Pion Inc 31 Mar 2025

Groundbreaking study reveals new pathways to modulate cell behavior

Cell membrane proteins hide secret gateways that can be used to modify cell behavior. This has been demonstrated in a study led by the Hospital del Mar Research Institute and published in Nature Communications, with participation from research centers in Spain, Switzerland, the United Kingdom, Germany, France, Poland, the Netherlands, Denmark, Hungary, Italy, Sweden, China, and the United States.

27 Mar 2025

Breakthrough discovery could lead to new class of antibiotics

The last time a new class of antibiotics reached the market was nearly three decades ago - but that could soon change, thanks to a discovery by researchers at McMaster University.

26 Mar 2025

New protein target could aid in muscle regeneration for degenerative conditions

For millions of people, losing muscle isn't just about weakness; it's about losing independence. Whether caused by Duchenne muscular dystrophy, aging or other degenerative conditions, muscle loss can make everyday activities – like walking, climbing stairs or even standing up – a daily struggle

26 Mar 2025

Natural product derivative demonstrates promising therapeutic potential for psoriasis

Announcing a new publication for Acta Materia Medica journal. Phosphodiesterase-4 (PDE4), a member of the phosphodiesterase superfamily, has highly important roles in cyclic nucleotide signaling pathways and a variety of skin disorders.

25 Mar 2025

ELRIG announces Prof Rory Johnson and Dr Shalini Andersson as keynote speakers at Therapeutic Oligonucleotides 2025

ELRIG, a not-for-profit, volunteer-led organization for the drug discovery community, today announced the keynote speakers for Therapeutic Oligonucleotides 2025 taking place at the AstraZeneca R&D site in Gothenburg, Sweden from 14-15 May. Prof Rory Johnson, Associate Professor, University College Dublin, and Dr Shalini Andersson, Vice President Nucleic Acid Therapeutics, AstraZeneca will lead this year's event focused on 'drugging the undruggable'.

25 Mar 2025

250,000 whole genomes sequenced for AGD initiative to advance drug discovery

Nashville Biosciences LLC (NashBio), a leading clinical and genomic data company and wholly owned subsidiary of Vanderbilt University Medical Center, and global DNA sequencing giant Illumina Inc. today announced that 250,000 whole genomes have been sequenced for the Alliance for Genomic Discovery (AGD) initiative.

21 Mar 2025

Drug Discovery News and Research

Further Reading

Nuclera expands eProtein Discovery capabilities to enable membrane protein production

Researchers analyze the mutational landscape of TMB-high colorectal cancer tumors

New antibiotic compound emerges as strong candidate in the fight against MRSA

Calibr-Skaggs receives FDA approval to test sCAR-T therapy in patients with autoimmune diseases

Advancing Adherent Cell Assays with SemaCyte® Technology

National Quantum Computing Centre launches Insights Paper exploring quantum computing's transformative potential in healthcare and pharmaceuticals

OICR funds five innovative cancer drug discovery projects

New structural and mechanistic understanding for cancer drug design

Mount Sinai launches AI center to revolutionize small molecule drug discovery

WHO releases first reports on shortages in fungal disease treatments and diagnostics

Assessing the impact of the particle drift effect on oral drug absorption using flux tools

Groundbreaking study reveals new pathways to modulate cell behavior

Breakthrough discovery could lead to new class of antibiotics

New protein target could aid in muscle regeneration for degenerative conditions

Natural product derivative demonstrates promising therapeutic potential for psoriasis

ELRIG announces Prof Rory Johnson and Dr Shalini Andersson as keynote speakers at Therapeutic Oligonucleotides 2025

250,000 whole genomes sequenced for AGD initiative to advance drug discovery

Natural compounds identified as potential inhibitors of SARS-CoV-2 spike protein

Scientists discover irreversible peptide inhibitors for undruggable cancer target

Sapio Sciences makes AI-Native drug discovery seamless with NVIDIA BioNeMo

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®